Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR). (February 2017) - Schmidinger, M.; Motzer, R.J.; Powles, T.; Escudier, B.; Tannir, N.M.; Mainwaring, P.N.; Rini, B.I.; Hammers, H.J.; Donscov, F.; Roth, B.; Peltola, K.; Lee, J.L.; et al.